Linking research to global health equity: The contribution of product development partnerships to access to medicines and research capacity building

American Journal of Public Health

Volumn 103, Issue 11, 2013, Pages 1968-1978

  Pratt, Bridget ^a   Loff, Bebe ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; CAPACITY BUILDING; DEVELOPING COUNTRY; ECONOMICS; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; MALARIA; NEGLECTED DISEASE; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH; NEGLECTED DISEASES; SUPPLY AND DISTRIBUTION;

CAPACITY BUILDING; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MALARIA; NEGLECTED DISEASES; PHARMACEUTICAL PREPARATIONS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RESEARCH; WORLD HEALTH; GLOBAL HEALTH;

EID: 84886400880     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2013.301341     Document Type: Article

References (56)

1. Widdus R, White K. Combating Diseases Associated With Poverty: Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships. Geneva, Switzerland: Initiative on Public-Private Partnerships for Health; 2004.
2. Public Health, Innovation, and Intellectual Property Rights: A Report of the Commission on Intellectual Property Rights, Innovation, and Public Health. Geneva, Switzerland: World Health Organization; 2006.
3. Institute of Medicine. The US Commitment to Global Health: Recommendations for the Public and Private Sectors. Washington, DC: National Academies Press; 2009:30.
4. Health is Global: A UK Government Strategy 2008-13. Norwich, UK: Her Majesty's Government; 2008.
5. Moran M, Guzman J, Henderson K, et al. Neglected Disease Research and Development: Is the Global Financial Crisis Changing R&D? Sydney, Australia: Policy Cures; 2011.
6. Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2005;2(9):e302.
7. Tucker TJ, Makgoba MW. Publicprivate partnerships and scientific imperialism. Science. 2008;320(5879): 1016-1017.
8. Pratt B, Loff B. Health research systems: promoting health equity or economic competitiveness? Bull World Health Organ. 2012;90(1):55-62.
9. Frost LJ, Reich M. Access: How Do Good Health Technologies Get to Poor People in Poor Countries? Cambridge, MA: Harvard Center for Population and Development Studies; 2008.
10. Lansang MA, Dennis R. Building capacity in health research in the developing world. Bull World Health Organ. 2004;82(10):764-770.
11. Drugs for Neglected Diseases. Available at: http://www.dndi.org. Accessed June 4, 2012.
12. Medicines for Malaria Venture. Available at: http://www.mmv.org. Accessed June 4, 2012.
13. Drugs for Neglected Diseases. DNDi annual report 2010: developing, implementing, consolidating. 2011. Available at: http://www.dndi.org/index.php/ annualreport.html. Accessed June 11, 2012.
14. Medicines for Malaria Venture. MMV annual report 2011. 2012. Available at: http://www.mmv.org/newsroom/publications/annual-report-2011. Accessed June 12, 2012.
15. Independent Evaluation Group. The Medicines for Malaria Venture. Washington, DC: World Bank; 2008.
16. Herman L, Oudin A. PDP access strategy discussion paper. 2010. Available at: http://pdpaccess.org/downloads/projects/full-papers/ PDP%20Access%20Strategy%20Discussion%20Paper.pdf. Accessed June 15, 2012.
17. Cohen J, Dibner MS, Wilson J. Development of and access to products for neglected diseases. PLoS ONE. 2010;5 (5):e10610.
18. Moran M, Guzman J, Ropars AL, Illmer A. The role of product development partnerships in research and development for neglected diseases. Int Health. 2010;2(2):114-122.
19. Nuyens Y. No Development Without Research: A Challenge for Capacity Strengthening. Geneva, Switzerland: Global Forum for Health Research; 2005.
20. Novartis and Medicines for Malaria Venture. Coartem Dispersible fact sheet. 2008. Available at: http://www.coartem.com/downloads/coartem- dispersiblefact-sheet.pdf. Accessed June 10, 2011.
21. Yun O, Priotto G, Tong J, Flevaud, L, Chappuis, F. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010;4(5):e720.
22. ISRCTN Register. A phase III, randomised, non-inferiority trial to assess the efficacy and safety of Dihydroartemisinin and Piperaquine in comparison with Artemether and Lumefantrine in children with uncomplicated plasmodium falciparum malaria. 2009. Available at: http://www.controlled-trials.com/ ISRCTN16263443. Accessed June 7, 2011.
23. Pfizer. Pfizer and Sigma-Tau announce an agreement to market a potential new treatment for malaria in Africa. 2008. Available at: http://www.pfizer.com/ news/press-releases/pfizer-press-release-archive.jsp#guid=20081209005784en& source=RSS-2008&page=1. Accessed June 14, 2011.
24. Denis MB, Davis TME, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis. 2002;35(12):1469-1476.
25. Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375(9724):1457-1467.
26. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374 (9683):56-64.
27. Bompart F, Kiechel JR, Sebbag R, Pecoul, B. Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience. Malar J. 2011;10:143.
28. Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011;9:15.
29. Drugs for Neglected Diseases Initiative. A new product delivered by an innovative partnership: ASMQ to treat malaria. 2008. Available at: http://www.dfid.gov.uk/r4d/PDF/Outputs/DNDI/ASMQ-Press-Pack.pdf. Accessed June 6, 2011.
30. ClinicalTrials.gov. Safety and efficacy study of Paromomycin to treat visceral leishmaniasis. 2005. Available at: http://clinicaltrials.gov/ct2/show/ NCT00216346. Accessed June 6, 2011.
31. Institute for One World Health. Available at: http://www.oneworldhealth. org. Accessed June 4, 2012.
32. Institute of One World Health. Paromomycin intramuscular injection. 2012. Available at: http://www.oneworldhealth.org/pdf/PMIM-Flyer-FINAL.pdf. Accessed January 18, 2013.
33. Central Intelligence Agency. CIA World Factbook. 2012. Available at: https://www.cia.gov/library/publications/the-world-factbook/rankorder/2004rank. html. Accessed January 18, 2013.
34. ACTwatch. Cambodia outlet baseline survey. 2009. Available at: http://www.actwatch.info/results/country-select.asp. Accessed June 10, 2011.
35. ACTwatch. Democratic Republic of Congo outlet baseline survey. 2009. Available at: http://www.actwatch.info/results/country-select.asp. Accessed June 10, 2011.
36. ACTwatch. Madagascar outlet baseline survey. 2009. Available at: http://www.actwatch.info/results/country-select. asp. Accessed June 10, 2011.
37. Amuasi JH, Diap G, Blay-Nguah S, et al. Access to artesunate-amodiaquine, quinine, and other anti-malarials: policy and markets in Burundi. Malar J. 2011;10:34.
38. Ensuring Success and Targeting Eradication: MMV Business Plan 2008-2012. Geneva, Switzerland: Medicines for Malaria Venture; 2008.
39. Mahoney RT. Product Development Partnerships: case studies of a new mechanism for health technology innovation. Health Res Policy Syst. 2011;9:33.
40. Drugs for Neglected Diseases Initiative, Sanofi Aventis. ASAQ press pack. 2008. Available at: http://r4d.dfid.gov.uk/PDF/Outputs/DNDI/ASAQ-press-pack. pdf. Accessed June 8, 2011.
41. Special Programme for Research and Training in Tropical Diseases. Implementation Research for the Control of Infectious Diseases of Poverty. Geneva, Switzerland: World Health Organization; 2011.
42. National Vector Borne Disease Control Programme (India). Guidelines on diagnosis and treatment of Kala-azar. 2011. Available at: http://www.nvbdcp.gov. in/Doc/Guidelines-Diagnosis-Treatment-KA.pdf. Accessed June 12, 2011.
43. Medicines for Malaria Venture. MMV annual report 2010. 2011. Available at: http://www.mmv.org/newsroom/publications/mmv-annual-report-2010. Accessed June 5, 2011.
44. Drugs for Neglected Diseases Initiative. DNDi annual report 2008-2009. 2009. Available at: http://www.dndi.org/annual-report.html?start=3. Accessed June 7, 2011.
45. Lutumba P, Kande K, Boelart M, Kayembe, JM, Mampunza, S. Research capacity strengthening in the DRC. Lancet. 2010;375(9720):1080.
46. Access to Medicine Foundation. The Access to Medicines Index 2012. 2012. Available at: http://www.accesstomedicineindex.org/sites/www. accesstomedicineindex.org/files/2012-access-to-medicine-index-full- reportclickable.pdf. Accessed January 17, 2013.
47. Access to Medicine Foundation. The Access to Medicines Index 2010. 2010. Available at: http://www.accessto medicineindex.org/sites/www.accessto medicineindex.org/files/2010-access-tomedicine-index.pdf. Accessed June 6, 2011.
48. GlaxoSmithKline. Corporate social responsibility report 2009. 2009. Available at: http://www.gsk.com/responsibility/downloads/GSK-CR-2009-full.pdf. Accessed June 21, 2011.
49. GlaxoSmithKline. Corporate social responsibility report 2008. 2008. Available at: http://www.gsk.com/responsibility/downloads/GSK-CR-2008-full.pdf. Accessed June 21, 2011.
50. GlaxoSmithKline. Corporate social responsibility report 2011. 2011. Available at: http://www.gsk.com/responsibility/downloads/GSK-CR-2011-Report. pdf# health-for-all. Accessed June 16, 2012.
51. MSF Campaign for Access to Essential Medicines. Untangling the web of antiretroviral price reductions. 2011. Available at: http://utw.msfaccess.org/ drugs. Accessed June 16, 2011.
52. GlaxoSmithKline. Corporate social responsibility report 2012. 2012. Available at: http://www.gsk.com/content/dam/gsk/globals/documents/pdf/ corporateresponsibility/cr-report-2012/gsk-cr-2012-report.pdf. Accessed May 3, 2013.
53. Moran M, Strub-Wourgaft N, Guzman J, et al. Registering new drugs for low-income countries: the African challenge. PLoS Med. 2011;8(2):e1000411.
54. World Health Organization. WHO/Health Action International Project on Medicine Prices and Availability. 2012. Available at: http://www.who.int/ medicines/areas/access/Medicine-Prices-and-Availability/en/index.html. Accessed June 6, 2012.
55. Task Force on Health Systems Research. The Millennium Development Goals Will Not Be Attained Without New Research Addressing Health System Constraints to Delivering Effective Interventions. Geneva, Switzerland: World Health Organization; 2005.
56. Rudan I, El Arifeen S, Black RE, Campbell H. Childhood pneumonia and diarrhoea: setting our priorities right. Lancet Infect Dis. 2007;7(1):56-61.